Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ELV001-201 in active rheumatoid arthritis
PACTR202602665148824Phase 2Not yet recruiting
- Sponsor
- Elevara Medicines
- Start
- Jan 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in rheumatoid arthritis (RA) comparing ELV001 add-on with Placebo add-on (2 arms). Primary endpoint: Efficacy of ELV001 as add-on treatment to standard-of-care in active rheumatoid arthritis. Planned start Jan 2026; status: not yet recruiting.
02
Drugs
ELV001
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on PACTR202602665148824.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202602665148824.